One works through amylin receptors. The other hits three incretin pathways at once. Neither is a GLP-1 drug in the usual sense. Here's how they actually compare.
Research purposes only. Both compounds are research peptides. This content is for educational reference only. Not medical advice.
These two compounds are often mentioned together because they're both potential "next generation" weight loss research compounds — but they're mechanistically about as different as two drugs in this category can be. Cagrilintide doesn't touch GLP-1 receptors at all. Retatrutide hits three separate incretin/metabolic receptors simultaneously.
Understanding what each does mechanistically is essential before comparing their data — because you're not comparing the same type of intervention.
| Feature | Cagrilintide | Retatrutide |
|---|---|---|
| Drug class | Amylin analog | GLP-1/GIP/glucagon triple agonist |
| Primary receptors | CALCR/RAMP1/RAMP3 (amylin) | GLP-1R, GIPR, GcgR |
| GLP-1 receptor activity | None | Primary mechanism |
| Appetite suppression | Via brainstem amylin receptors | Via GLP-1 + GIP hypothalamic pathways |
| Energy expenditure | Minimal direct effect | Glucagon receptor increases thermogenesis |
| Gastric emptying | Slows (amylin-mediated) | Slows (GLP-1-mediated) |
| Glucagon | Suppresses postprandial glucagon | Activates glucagon receptor (metabolic effect) |
| Half-life | ~7 days | ~6 days |
| Dosing frequency | Once weekly | Once weekly |
| Developer | Novo Nordisk | Eli Lilly |
Key mechanistic insight: These compounds don't compete — they're complementary. Cagrilintide + semaglutide (CagriSema) stacks an amylin pathway on top of a GLP-1 pathway. Retatrutide extends within the incretin system by adding GIP and glucagon on top of GLP-1. These are different strategies for hitting metabolic weight regulation from multiple angles.
On raw numbers, retatrutide's Phase 2 data is more impressive — but the comparison requires context. The retatrutide trial ran 48 weeks vs cagrilintide's 26 weeks, and the populations and designs differed. A direct head-to-head trial hasn't been run.
The more interesting comparison is CagriSema vs retatrutide — because Novo Nordisk's combination product is the real commercial bet. CagriSema Phase 2 data showed weight loss numerically superior to cagrilintide alone, and Phase 3 results will determine whether the combination can match or exceed retatrutide's numbers.
Both compounds produce dose-dependent nausea and GI side effects during titration — similar to what's seen with approved GLP-1 drugs. Retatrutide's glucagon component can produce additional effects (modest heart rate increase) not seen with cagrilintide. Neither has the cardiovascular outcome trial data that semaglutide and tirzepatide have accumulated over years of post-approval study.
24.2% at 48 weeks is the highest weight loss figure from any single-compound research peptide with published Phase 2 data. The triple agonist mechanism — particularly the glucagon-driven thermogenic component — appears to be driving results beyond what dual agonists achieved.
The amylin receptor system is non-redundant with GLP-1 pathways. Cagrilintide is the only long-acting amylin analog in research — it fills a mechanistic niche that retatrutide doesn't cover. For researchers studying amylin biology or CagriSema-style combinations, it's the relevant compound.
Not an either/or question: These compounds aren't competing for the same receptor slot. The better framing is: what mechanism are you studying? GLP-1/GIP/glucagon synergy → retatrutide. Amylin pathway → cagrilintide. Amylin + GLP-1 combination → CagriSema design.
COA-verified sources, current pricing with promo codes for both compounds.
Browse the Database → Dosage Calculator